Staburo Top Company 2026 

We’re happy to share that Staburo has once again been awarded as Kununu Top Company 2026, and we’ve now received this recognition three years in a row (2024, 2025, 2026). 

What makes this award special: it’s based on independent reviews from employees on Kununu, and only around 5% of employer profiles qualify each year. 

A huge thank you to our team for your honest feedback. Your daily commitment continue to shape a culture built on collaboration, trust, and continuous growth. 

We’re always looking for talented people who are passionate about using data science to make a real impact, helping to improve and save lives. Feel free to check out our open roles on our careers page. 

Biomarkers at Staburo

In 2024 at Staburo was about building momentum in the area Biomarkers. Deepening our engagement in the PSI Biomarker SIG, strengthening collaborations, and developing the ideas that would later become deliverables.

In 2025, we developed and released ShadowVIMP, an R package for variable selection in random forests, submitted the accompanying manuscript, and presented the work broadly in six presentations. Our involvement in the PSI Biomarker SIG continued to grow. The co-leadership of the group was transitioned to Mathias Cardner (AstraZeneca) and Laura Schlieker, and our Staburo colleagues were actively involved in the substreams throughout the year. Rebecca Freudling and Stephan Bischofberger joined the ctDNA subteam and supported an in-depths literature review on analysis standards for this biomarker. Together with many other colleagues from the industry Laura Schlieker supported the hands-on project of the AI/ML workstream and presented the work in a poster  at the PSI Conference in London. The group’s work was recognized with the Poster Prize.

Alongside scientific progress, we invested in team culture and connection, with highlights including a Munich rally and a team dinner for Indian food.

Looking ahead to 2026, we will continue our PSI activities at the PSI Conference in Belfast, where we will organize a joint session with the Treatment Effect Heterogeneity SIG. Besides other interesting talks the session will feature a presentation of outcomes from the AI/ML substream (presented by Laura Schlieker), and we are also looking forward to Maria Blanco presenting in the Young Statistician session.

After an inspiring and insightful week of feedback workshops conducted by BerlinAlley, we wrapped things up in the most festive way possible: our annual Christmas party!

We kicked off the evening in the company canteen, where the smell of homemade Glühwein and Punsch set the perfect holiday mood. Naturally, no Christmas gathering in Staburo would be complete without an abundant supply of Lebkuchen, because if you know us, you know that having enough Lebkuchen isn’t just a tradition, it’s practically a core value.

Once everyone was warmed up, the real adventure began. We headed out into the heart of Munich for a treasure hunt that challenged our teamwork and creativity. With quizzes and photo challenges, each team made their way through the city in search of clues. The mission: uncover the secret password required to enter our dinner location.

Step by step, clue by clue, we finally arrived, password in hand, ready for the next highlight of the evening. Inside, a cozy atmosphere and delicious food awaited us. We spent the rest of the night enjoying great conversations and laughter, an ideal ending to a busy and inspiring week!

Merry Christmas to everyone!

Staburo @ PSI/EFSPI Vaccines Statistics Workshop

On October 23, 2025, Staburo, represented by Tim Müller, attended the PSI/EFSPI Vaccines Statistics Workshop at the GSK site in Wavre. The workshop brought together a focused group of highly knowledgeable statisticians and researchers working in vaccines and infectious diseases. 

Tim enjoyed meeting familiar and new faces, and had engaging discussions with speakers and participants alike. Sessions on surrogate and correlates of protection, Bayesian methods, and modeling approaches sparked particularly interesting conversations. 

GSK was great at hosting the event on their site, providing an excellent setting for knowledge exchange and collaboration. Overall, it was an inspiring day that highlighted the exciting work happening in infectious disease statistics. Staburo is proud to contribute to this field and looks forward to continuing these discussions with peers and collaborators. 

Staburo contributes to bioinformatic analysis in a Phase 2 chronic kidney disease (CKD) study

We are pleased that part of our work got published as a scientific article in the International Journal of Molecular Sciences on November 7^th, 2025.

In this publication, we supported the bioinformatic analysis in a study investigating the effect of Vicadrostat monotherapy or in combination with Empagliflozin on urinary extracellular vesicle microRNA expression.

Staburo assisted in data analysis and visualisation, as well as in biological interpretation, identifying the modulation of miRNA profiles under the treatments in the study, highlighting the potential use of microRNAs as biomarkers for disease activity and treatment response in CKD.

DOI: https://doi.org/10.3390/ijms262210810